ASND
Ascendis Pharma A/S$230.83
-1.19%LiveJun 18, 2026
Market cap
$14.34B
52w range
160.86 – 250.74
P / E
—
EPS
—
Volume
908.47K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Ascendis Pharma A/S’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $287.50 (+24.55%)
Candlestick · 1Y
Open in chart workstation →ASND
230.83+31.32%H 250.74L 160.86MA50 231.76MA200 217.83Avg vol 594K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14% | +4.45% | -6.74% | +4.03% | +15.42% | +8.25% | +31.32% | +149.57% | +63.80% | +1579.99% | +1125.86% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$228.60
16,764 sh
Bid
$212.00
12 sh
Ask
$245.00
2 sh
Spread
$33.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
Recent analyst activity
DB- Jun 09, 2026GradeOutperform → OutperformOppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)Oppenheimer
Peers
No peer list available for ASND.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|